Supriya Lifescience hosts virtual investor meeting on September 17

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Supriya Lifescience Ltd to hold virtual investor meet on September 17, 2026
  • Session scheduled from 11:00 am to 12:00 noon as a group meeting
  • Disclosure made under SEBI LODR Regulation 30(6)
  • Investor presentation uploaded to stock exchanges and company website
powered bylight_fuzz_icon
50675494

*this image is generated using AI for illustrative purposes only.

Supriya Lifescience will host a virtual analyst and investor meeting on September 17, 2026, from 11:00 am to 12:00 noon. The company disclosed the schedule under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Meeting details

The event is structured as a group meeting with investors. Officials from Supriya Lifescience Limited will interact directly with analysts and institutional investors. The session will be conducted in a virtual format.

Parameter Details
Event Investor Group Meeting
Date September 17, 2026
Time 11:00 am – 12:00 noon
Format Group Meeting
Mode Virtual

The company has uploaded the investor presentation to the stock exchanges and its website for public access. The date is subject to change due to exigencies on the part of the company or participants.

Historical Stock Returns for Supriya Lifescience

1 Day5 Days1 Month6 Months1 Year5 Years
+4.48%+12.14%+21.82%+67.96%+31.35%+151.04%

What specific strategic initiatives or pipeline developments is Supriya Lifescience likely to highlight in the upcoming investor presentation?

How might the insights shared in this September 2026 meeting influence analyst price targets and institutional sentiment towards the stock?

Are there any pending regulatory approvals or clinical trial results for key products that investors are expecting management to address during the session?

Supriya Lifescience sets Sept 24 AGM; releases FY26 annual report link

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Supriya Lifescience schedules 18th AGM for September 24, 2026, via video conferencing
  • Board seeks approval for final dividend of Re. 1.00 per equity share for FY26
  • Company releases weblink for FY26 Annual Report and AGM notice on its website
  • Record date for dividend eligibility is set as September 4, 2026
powered bylight_fuzz_icon
49294999

*this image is generated using AI for illustrative purposes only.

Supriya Lifescience has scheduled its 18th Annual General Meeting (AGM) for Thursday, September 24, 2026. The meeting will be conducted through Video Conferencing or Other Audio Video Means (OAVM). The Board of Directors recommended a final dividend of Re. 1.00 per equity share for FY26 during its meeting on May 27, 2026. This proposal is subject to shareholder ratification at the AGM.

The company has also intimated the weblink for the Annual Report and AGM notice for FY26. Shareholders can access the soft copy of the Annual Report and the Notice convening the 18th AGM via the path provided on the company’s website. Physical copies were sent to shareholders who have not registered their email addresses with the company, depositories, or the Registrar and Transfer Agent (RTA), MUFG Intime India Pvt. Ltd., as on the cut-off date of August 21, 2026.

Financial Performance

FY26 marked the company's highest-ever annual revenue and EBITDA. Revenue from operations grew 18.9% year-on-year to ₹8,278.75 crore. Profit after tax increased 11.2% to ₹2,091.20 crore. EBITDA rose 12.8% to ₹294.1 crore, with margins at 35.5%. The company delivered strong demand across core therapeutic segments, supported by backward integration and disciplined execution.

Metric FY26 FY25 Change
Revenue ₹8,278.75 crore ₹6,964.85 crore +18.9%
EBITDA ₹294.1 crore ₹261.0 crore +12.8%
Net Profit ₹2,091.20 crore ₹1,879.58 crore +11.2%

Business Responsibility & Sustainability Report

The company released its fourth Business Responsibility and Sustainability Report (BRSR) for FY26. Key operational highlights include:

  • Global Reach: Exports account for 82% of total turnover, with the company serving customers in 128 countries.
  • Workforce: Total employees stood at 1,310. The board comprises 40% women, while key management personnel include 50% women.
  • Safety: The company reported zero lost-time injuries and zero fatalities in FY26.
  • Environmental: Total energy consumption was 223,789.94 GJ. Scope 1 and Scope 2 greenhouse gas emissions intensity decreased to 1.89 TCO2e per million rupees of turnover, down from 2.00 TCO2e in FY25.
  • Waste Management: Total waste generated increased to 884.69 metric tonnes from 87.71 metric tonnes in the previous year, largely driven by construction and demolition waste.

Dividend Details

The final dividend will be paid within 30 days of the AGM, provided it receives member approval. Eligibility is determined by the names appearing in the Register of Members as on the record date of September 4, 2026. The dividend payout represents an outflow of ₹80.48 million.

Strategic Updates

Backward-integrated products accounted for 76% of revenue, supporting cost competitiveness. The company successfully completed an unannounced USFDA inspection at its Lote facility in February 2026, receiving its Establishment Inspection Report with one minor observation. Capital expenditure of ₹152 crore was directed largely towards the Ambernath facility, which extends manufacturing into formulations and contract manufacturing.

Board Re-appointments

Shareholders will vote on the re-appointment of Dr. Saloni Satish Wagh and Ms. Shivani Satish Wagh, who retire by rotation. Dr. Saloni Wagh serves as Managing Director, overseeing export, marketing, and business development. She holds a PhD in Chemistry and has been associated with the company since 2014. Ms. Shivani Wagh serves as Joint Managing Director, focusing on exports to Europe. She holds a master's degree in international business management from the University of Manchester. Both directors attended four board meetings in FY25-26 and hold 1,02,375 shares each (0.13%).

Special Business

The AGM agenda includes ratifying the remuneration of Cost Auditors for FY 2026-27. The Board appointed M/s. Rampurawala Mohammed A & Co as Cost Auditors for a fee of ₹2.50 lakh plus applicable tax and out-of-pocket expenses. This appointment is subject to shareholder approval via an ordinary resolution.

Historical Stock Returns for Supriya Lifescience

1 Day5 Days1 Month6 Months1 Year5 Years
+4.48%+12.14%+21.82%+67.96%+31.35%+151.04%

How will the expansion into formulations and contract manufacturing at the Ambernath facility impact Supriya Lifescience's revenue mix and margin profile in FY27?

Given that exports constitute 82% of turnover, what are the potential risks to future growth from evolving regulatory landscapes or trade policies in key markets like the US and Europe?

With waste generation increasing significantly due to construction activities, how does management plan to mitigate environmental compliance risks and maintain its sustainability ratings?

More News on Supriya Lifescience

1 Year Returns:+31.35%